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A commentary on
Next Generation Sequencing and Linkage Analysis for the Molecular Diagnosis of a Novel
Overlapping SyndromeCharacterized byHypertrophic Cardiomyopathy andTypical Electrical
Instability of Brugada Syndrome
by Mango, R., Luchetti, A., Sangiuolo, R., Ferradini, V., Briglia, N., Giardina, E., et al. (2016). Circ.
J. 80, 938–949. doi: 10.1253/circj.CJ-15-0685
We read with great interest a recently published report by Mango et al. (2016) describing for the
first time an association between hypertrophic cardiomyopathy (HCM), Brugada syndrome (BrS),
and an α-tropomyosin (TPM1) gene missense mutation (c.574G>A; p.E192K) identified using a
combined approach of integrated linkage analysis and next generation sequencing (NGS). Using
NGS enables the analysis of a large number of genes quickly and simultaneously and at a reasonable
cost, but the amount of information obtained is extremely large and difficult to interpret. Using
integrated linkage analysis to narrow the focus of the NGS limited the amount of data obtained to
an amount that could be more easily analyzed. Thus, the authors were able to quickly identify the
tropomyosin mutation found in the family members affected with clinical characteristics of both
HCM and BrS.
Other studies support the idea that arrythmogenic sudden death, even in the absence of overt
structural abnormalities, can be directly linked to altered sarcomeric properties (Baudenbacher
et al., 2008). HCM is associated with a high susceptibility to sudden death (Alves et al., 2014) and
has long been linked to myofilament mutations (Yar et al., 2014; van der Velden et al., 2015). To
investigate the functional effect of the E192K mutation in tropomyosin, Mango et al. investigated
in silico the effect of the interaction between TPM1 and polycystin-2 protein (PKD2), which is
an intracellular Ca2+ channel that interacts with different sarcomeric proteins regulating Ca2+
signaling (Mango et al., 2016). The modeling experiments suggested that the E192K mutation
can result in significant changes in tropomyosin structure by disrupting the formation of the
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homodimeric coiled-coil quaternary structure, leading to
disruption of the ability of TPM1 to interact with PKD2,
potentially altering the function of PKD2 in regulating Ca2+ ion
flux. The tropomyosin E192K mutation has never before been
associated with BrS, and thus this is an interesting finding that
provides an indication for future experiments that should spark
much interest in the field, especially since BrS is commonly
thought to originate as a channelopathy. Commonly, the
explanation given for the ECG abnormalities observed in BrS
is that BrS is a channelopathy characterized by ion channel
dysfunction and that it has been linked to mutations in genes
encoding for subunits of cardiac sodium, potassium, and Ca2+
channels, the most common mutation being SCN5A, which
accounts for 15–30% of BrS cases (Kapplinger et al., 2010).
However, although it is the most common mutation found
in BrS, the SCN5A mutation is not found in the majority of
BrS patients. Thus, no single causal factor appears to link all
BrS patients (Amin et al., 2008). The results of Mango et al.
present a novel and interesting finding that BrS may not always
originate as ion channel dysfunction, but may also originate as
myofilament pathologies that alter Ca2+ signaling. This provides
an indication for future experiments to investigate sarcomeric
alterations in BrS.
While the results presented by Mango et al. are thought-
provoking and provide justification for future inquiries, caution
should be taken in concluding that for certain an overlap between
HCM and BrS is caused by the specific tropomyosin mutation
described. The number of participants for the study is only
seven, and only four of which exhibit clinical manifestations of
HCM and BrS and carry the mutation. Importantly, all of the
participants are from the same family. Thus, it is important to
verify the findings in a larger patient population and in other
families.
Flecainide or ajmaline can be used to provoke the type 1 BrS
ECG pattern in patients to confirm the diagnosis of BrS. Mango
et al. administered the flecainide test to diagnose BrS in the
patients who carry the tropomyosin mutation. As future studies
are performed to verify the results of Mango et al., it is important
to note that flecainide is less effective than ajmaline in unveiling
the type 1 BrS ECG pattern. In fact, in one study, only 68% of
patients who tested positive with an ajmaline test were positive
with the flecainide test (Wolpert et al., 2005). Therefore, it would
be better to use ajmaline, rather than flecainide, to affirmatively
diagnose BrS in future studies. The occurrence of false negatives
could mislead researchers who attempt to verify the results of
Mango et al. or who use this approach to diagnose new clinical
entities.
In conclusion, caution should be taken in concluding that
the α-tropomyosin gene missense mutation identified is for
certain the cause of a novel overlapping clinical entity without
confirmation in a larger sample size. Nevertheless, Mango
et al. have for the first time identified a sarcomeric mutation
associated with BrS, and this warrants further investigation
and is of great interest to the field, suggesting that BrS
may not always originate as ion channel dysfunction, but
may also originate as myofilament pathologies that alter Ca2+
signaling.
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